News Quantified

CYCN – cyclerion therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Cyclerion Therapeutics (NASDAQ:CYCN) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

EXCLUSIVE: Cycurion Wins $1 Million+ Contract To Modernize Federal Emergency Warning Network [Yahoo! Finance]

Cyclerion Therapeutics, Inc. (CYCN) Discusses On Pioneering A New Era In Neuropsychiatric Therapies Call (Transcript) [Seeking Alpha]

Cyclerion Therapeutics, Inc. - Pre Recorded Special Call [Seeking Alpha]

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company [Yahoo! Finance]

Form 8-K Cyclerion Therapeutics, For: Dec 01

Form 10-Q Cyclerion Therapeutics, For: Sep 30

Form 10-K/A Cyclerion Therapeutics, For: Dec 31

Form SCHEDULE 13G Cyclerion Therapeutics, Filed by: J. WOOD CAPITAL ADVISORS LLC

Form 8-K Cyclerion Therapeutics, For: Sep 19

Top News Gainers

1/13 Form 8-K Cyclerion Therapeutics, For: Jan 13 9.3%

4/2 Form 4 Cyclerion Therapeutics, For: Mar 31 Filed by: Hecht Peter M 7.0%

12/27 Form SC 13G Cyclerion Therapeutics, Filed by: EcoR1 Capital, LLC 6.7%

3/12 Form 10-K Cyclerion Therapeutics, For: Dec 31 6.4%

6/17 Form SC 13G Cyclerion Therapeutics, Filed by: Camber Capital Management LP 5.0%

2/25 Form 4 Cyclerion Therapeutics, For: Feb 21 Filed by: Huyett William 3.2%

12/13 Cyclerion Therapeutics, Inc. (CYCN) Is Burning These Hedge Funds [Yahoo! Finance News] 3.2%

2/3 Form SC 13G Cyclerion Therapeutics, Filed by: Artal International S.C.A. 3.0%

8/12 Form 10-Q Cyclerion Therapeutics, For: Jun 30 2.9%

5/9 Cyclerion Therapeutics: This Spinoff Has Multiple Readouts Coming Up, Concerns Remain [Seeking Alpha] 2.5%

Top News Decliners

6/3 Cyclerion Therapeutics Inc (NASDAQ: CYCN) is now covered by analysts at Credit Suisse Group AG. They set a "neutral" rating on the stock. -18.7%

3/5 Form 8-K Cyclerion Therapeutics, For: Feb 28 -12.0%

5/13 Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company -9.4%

6/4 Form 4 Cyclerion Therapeutics, For: Jun 01 Filed by: CONRADES GEORGE H -6.6%

12/31 Form 4 Cyclerion Therapeutics, For: Dec 27 Filed by: Currie Mark G -5.5%

8/12 Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months -5.5%

11/27 Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference -4.8%

9/20 Form 4/A Cyclerion Therapeutics, For: Apr 01 Filed by: Huyett William -3.5%

10/8 Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings -3.1%

2/7 Form SC 13G Cyclerion Therapeutics, Filed by: FMR LLC -2.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day